lanadelumab   Click here for help

GtoPdb Ligand ID: 9094

Synonyms: DX-2930 | lanadelumab-flyo | Takhzyro® | X124-G01
Approved drug
lanadelumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Lanadelumab is a fully human monoclonal antibody targeting the serine peptidase kallikrein B1 (KLKB1, a.k.a. plasma kallikrein). It is generated in recombinant Chinese hamster ovary cells.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US8816055 [5].
Click here for help
1. Anderson M. 
We are finally unravelling the mystery of what causes severe covid-19.
Accessed on 22/09/2020. Modified on 22/09/2020. New Scientist,
2. Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D. (2020)
A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Elife, 9. DOI: 10.7554/eLife.59177 [PMID:32633718]
3. Robinson EL, Alkass K, Bergmann O, Maguire JJ, Roderick HL, Davenport AP. (2020)
Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes.
J Mol Cell Cardiol, 147: 88-91. [PMID:32818486]
4. Roche JA, Roche R. (2020)
A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.
FASEB J, 34 (6): 7265-7269. [PMID:32359101]
5. Sexton DJ, Viswanathan M. (2014)
Plasma kallikrein binding proteins.
Patent number: US8816055 B2. Assignee: Dyax Corp.. Priority date: 06/01/2011. Publication date: 26/08/2014.